CLINICAL NEWS and OS rates were similar regardless of refractory subgroup . Median OS ( estimated from the time salvage therapy for refractory disease was initiated ) was 6.3 months ( range not provided ) in the entire cohort . However , although the researchers observed a higher response rate among patients in the post-AHCT group , median OS in this group was similar to those of the other refractory subgroups ( 6.2 months for patients who relapsed ≤12 months post- AHCT ; 7.1 months for those who were primary-refractory ; and 6.1 months for those who were refractory to second- or later-line therapy ; p value not reported ; see TABLE 3 on page 50 ).
When the investigators compared OS outcomes across different patient subgroups , they determined that patients who achieved a CR after last salvage chemotherapy had longer median OS ( 14.9 months ; range not reported ), compared with non-responders ( 4.6 months ; range not reported ). Median OS was also longer among those who had undergone AHCT ( n = 180 ; 14.4 months ; range not reported ) than those who did not ( n = 423 ; 5.1 months ; range not reported ; p values not reported ).
Other factors that were significantly associated with OS included :
“ Even with the availability of multiple rituximab-based regimens , outcomes ... remain dismal across global centers and trials .”
— MICHAEL CRUMP , MD
FACTOR REPLACEMENT MIRRORS THE PROTECTION WITHIN
• Eastern Cooperative Oncology Group performance status ( 0-1 vs . ≥2 ; p < 0.0001 )
• disease stage ( I-II vs . III-IV ; p < 0.001 )
• IPI risk groups ( low vs . lowintermediate [ p < 0.001 ]; low-intermediate vs . highintermediate [ p < 0.1 ])
“ These data are particularly important , because they represent a large number of patients treated in the modern rituximab era , suggesting that even with the availability of multiple rituximab-based regimens , outcomes among patients with refractory DLBCL remain dismal across global centers and trials ,” the authors concluded .
“ Despite potential differences in patient populations and study design , outcomes were quite homogeneous ,” the authors reported . However , the study is limited by its retrospective design and variance among data in the analyzed studies . “ For example , the time period of patients ’ treatment may influence the applicability of the benchmark to future studies ,” they added .
Kite Pharma contributed to the funding of the study .
The authors report receiving funding from Kite Pharma .
REFERENCE
Crump M , Neelapu SS , Farooq U , et al . Outcomes in refractory diffuse large B-cell lymphoma : results from the international SCHOLAR-1 study . Blood . 2017 August 3 . [ Epub ahead of print ]
For your patients with Hemophilia A , Factor treatment has a long history of results . 1 It temporarily replaces what ’ s missing and is regulated by the natural hemostatic process to form a proper clot . 2-5
Brought to you by Shire , dedicated to pursuing advancements in hemophilia for more than 60 years .
Explore an established treatment option in hemophilia
References : 1 . Franchini M , Mannucci PM . The history of hemophilia . Semin Thromb Hemost . 2014 ; 40:571-576 . 2 . Peyvandi F , Garagiola I , Young G . The past and future of haemophilia : diagnosis , treatments , and its complications . Lancet . 2016 ; 388:187-197 . 3 . Lenting PJ , van Mourik JA , Mertens K . The life cycle of coagulation factor VIII in view of its structure and function . Blood . 1998 ; 92 ( 11 ): 3983-3996 . 4 . Antovic A , Mikovic D , Elezovic I , Zabczyk M , Hutenby K , Antovic JP . Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand . Thromb Haemost . 2013 ; 111 ( 4 ): 656-661 . 5 . Hvas AM , Sørensen HT , Norengaard L , Christiansen K , Ingerslev J , Sørensen B . Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A . J Thromb Haemost . 2007 ; 5:2408-2414 .
© 2017 Shire US Inc ., Lexington , MA 02421 . All rights reserved . 1-800-828-2088 . SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates . S31962 05 / 17
ASHClinicalNews . org